MDASI AML/MDS Module
The MD Anderson Symptom Inventory for acute myeloid leukemia/myelodysplastic syndrome (MDASI-AML/MDS) is a disease site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-AML/MDS also assesses 4 symptom items specific to acute myeloid leukemia and myelodysplastic syndrome:
- feeling of malaise (not feeling well)
- diarrhea (loose stools)
- muscle weakness
- skin problems
Order the MDASI-AML/MDS
MDASI-AML/MDS Features
- Purpose: To assess the severity of multiple symptoms related to AML/MDS and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by AML/MDS and their treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91
MDASI-AML/MDS Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English |
MDASI User's Guide
In response to the FDA's 2009 guidance for the pharmaceutical industry on the use of PRO measures in medical product development to support labeling claims, we have prepared a MDASI User's Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-AML/MDS. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-AML/MDS References
Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5): 641-7, 2013.
Williams LA, Ahaneku H, Cortes JE, et al. Comparison of symptom burden in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [abstract]. American Society of Hematology (ASH) 56th Annual Meeting and Exposition, San Francisco CA, Dec 6-9, 2014. Blood 124(21), 2014; Abstract # 2652.
Every MDASI Module Contains...
All 13 MDASI core symptoms
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
All 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
The MDASI-AML/MDS is an easily administered and scored measure of symptom burden that can be used in clinical practice for consistent routine symptom assessment and in research to develop evidence for effective symptom-management interventions.
Loretta A. Williams, Ph.D., R.N.
Associate Professor, Symptom Research